Importantly, recent marketing authorization of a new drug for NSCLC treatment, amivantamab, targeting EGFR with exon 20 insertions (4–10% EGFR-positive cases) extends the list of molecular alterations that require accurate, sensitive and comprehensive analysis during the diagnostic process [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.